Corcept Therapeutics Inc
CORT71.880USD
-0.130-0.18%
Cierre 07/11, 16:00（ET）Cotizaciones retrasadas 15 min
7.62BCap. mercado
56.85P/E TTM
Más Datos de Corcept Therapeutics Inc Compañía
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Información de la empresa
Símbolo de cotizaciónCORT
Nombre de la empresaCorcept Therapeutics Inc
Fecha de salida a bolsaApr 15, 2004
Fundada en1998
Director ejecutivoDr. Joseph K. Belanoff, M.D.
Número de empleados500
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 15
Dirección101 Redwood Shores Parkway
CiudadREDWOOD CITY
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94065
Teléfono16506888803
Sitio Webhttps://www.corcept.com/
Símbolo de cotizaciónCORT
Fecha de salida a bolsaApr 15, 2004
Fundada en1998
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
-1.34%
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+5.82%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+54.67%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
107.40K
--
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
35.79K
-4.90%
Mr. Atabak Mokari
Mr. Atabak Mokari
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.06K
+7.91%
Mr. Joseph Douglas Lyon
Mr. Joseph Douglas Lyon
Chief Accounting and Technology Officer
Chief Accounting and Technology Officer
10.07K
--
Mr. William Guyer, Pharm.D.
Mr. William Guyer, Pharm.D.
Chief Development Officer
Chief Development Officer
5.49K
--
Mr. Gregg Huber Alton, J.D.
Mr. Gregg Huber Alton, J.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
-1.34%
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+5.82%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+54.67%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
107.40K
--
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
35.79K
-4.90%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
12.28%
The Vanguard Group, Inc.
9.39%
Ingalls & Snyder LLC (Asset Management)
7.30%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.01%
Other
60.23%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
12.28%
The Vanguard Group, Inc.
9.39%
Ingalls & Snyder LLC (Asset Management)
7.30%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.01%
Other
60.23%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
35.90%
Investment Advisor
31.21%
Individual Investor
11.55%
Hedge Fund
8.44%
Research Firm
1.58%
Pension Fund
1.03%
Sovereign Wealth Fund
0.82%
Bank and Trust
0.51%
Family Office
0.06%
Other
8.89%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
722
96.66M
91.15%
-8.10M
2025Q1
746
97.45M
92.10%
-9.12M
2024Q4
673
98.29M
93.20%
-10.89M
2024Q3
625
101.82M
97.42%
-10.51M
2024Q2
589
103.22M
99.09%
-12.69M
2024Q1
582
107.51M
103.94%
+2.98M
2023Q4
555
98.31M
95.40%
-4.22M
2023Q3
540
96.45M
94.14%
-5.68M
2023Q2
523
94.35M
92.83%
-12.18M
2023Q1
528
100.60M
93.30%
-751.20K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
13.02M
12.28%
-611.02K
-4.48%
Mar 31, 2025
The Vanguard Group, Inc.
9.96M
9.39%
-133.66K
-1.32%
Mar 31, 2025
Ingalls & Snyder LLC (Asset Management)
7.74M
7.3%
-357.16K
-4.41%
Mar 31, 2025
Renaissance Technologies LLC
6.14M
5.79%
-55.57K
-0.90%
Mar 31, 2025
Baker (George Leonard Jr.)
5.31M
5.01%
--
--
Apr 17, 2025
Parallel Advisors, LLC
3.97M
3.75%
+142.78K
+3.73%
Mar 31, 2025
State Street Global Advisors (US)
3.40M
3.21%
-146.42K
-4.13%
Mar 31, 2025
Belanoff (Joseph K)
2.98M
2.81%
-40.35K
-1.34%
Apr 17, 2025
Wilson (James N)
2.35M
2.21%
+129.14K
+5.82%
Apr 17, 2025
Geode Capital Management, L.L.C.
2.26M
2.13%
+191.89K
+9.28%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
SPDR S&P Pharmaceuticals ETF
5.35%
Invesco S&P SmallCap Health Care ETF
5.17%
Pacer US Small Cap Cash Cows Growth Leaders ETF
4.73%
Formidable ETF
4.13%
Invesco Pharmaceuticals ETF
3.79%
First Trust NYSE Arca Biotechnology Index Fund
3.55%
iShares U.S. Pharmaceuticals ETF
3.46%
Invesco S&P SmallCap Momentum ETF
3.09%
Invesco S&P SmallCap Quality ETF
2.96%
Invesco S&P SmallCap 600 Pure Growth ETF
1.9%
Ver más
SPDR S&P Pharmaceuticals ETF
Proporción5.35%
Invesco S&P SmallCap Health Care ETF
Proporción5.17%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporción4.73%
Formidable ETF
Proporción4.13%
Invesco Pharmaceuticals ETF
Proporción3.79%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.55%
iShares U.S. Pharmaceuticals ETF
Proporción3.46%
Invesco S&P SmallCap Momentum ETF
Proporción3.09%
Invesco S&P SmallCap Quality ETF
Proporción2.96%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporción1.9%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
